APVO Share Price | Aptevo Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Aptevo Therapeutics, Inc.?

Market Cap: As of Jun 18, Aptevo Therapeutics, Inc. has a market capitalization of 2.13 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Aptevo Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -23.70 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 4.75 million and total assets of 15.59 million.

Q: What does Aptevo Therapeutics, Inc. do?

Overview: Aptevo Therapeutics, Inc. is a biotechnology company focused on oncology and hematology therapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market cap: USD 2.13 Million (Micro Cap)Key Metrics: Debt Equity: 1.45 Return on Equity: 1,609.23% Price to Book: -1.45Contact Details: Address: 2401 4th Ave Ste 1050, SEATTLE WA: 98121-3460 Tel: 1 206 8380500 Fax: 1 206 8380503 Website: http://aptevotherapeutics.com/

Q: Is Aptevo Therapeutics, Inc. overvalued or undervalued?

As of 5 October 2023, Aptevo Therapeutics, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.1, and a return on equity of 8.5%. When compared to peers such as Amgen, which has a price-to-earnings ratio of 18.5, and Regeneron Pharmaceuticals with a price-to-book ratio of 3.0, Aptevo appears to be trading at a discount. This valuation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price.

Q: Is Aptevo Therapeutics, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Aptevo Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and Dow Theory both signaling bearish trends. The weekly MACD and KST are mildly bullish, but this is overshadowed by the bearish signals from the Bollinger Bands and the monthly KST. There is no available return data to compare the company's performance against the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.04 k

Shareholding (Dec 2025)

FII

0.02%

Held by 6 FIIs

DII

98.0%

Held by 2 DIIs

Promoter

0.00%

How big is Aptevo Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Aptevo Therapeutics, Inc. has a market capitalization of $2.13 million, with net sales of $0.00 million and a net profit of -$23.70 million over the latest four quarters. The company reported shareholder's funds of $4.75 million and total assets of $15.59 million as of Dec 24.

View full answer

What does Aptevo Therapeutics, Inc. do?

22-Jun-2025

Aptevo Therapeutics, Inc. is a biotechnology company specializing in oncology and hematology therapeutics, classified as a micro-cap with a market cap of $2.13 million and a recent net profit of -$6 million.

View full answer

Is Aptevo Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Aptevo Therapeutics, Inc. is considered attractive due to its undervaluation, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.1, making it cheaper than peers like Amgen and Regeneron, while also showing strong stock performance relative to the Sensex.

View full answer

Is Aptevo Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Aptevo Therapeutics, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and Dow Theory, despite some mildly bullish signals from weekly MACD and KST.

View full answer

Compare Aptevo Therapeutics, Inc. with Similar Stocks

60 Degrees Pharmaceuticals, Inc.Bio-Path Holdings, Inc.Revelation Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.21

Return on Equity

-160.72%

Price to Book

0.27

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.82%

6 Months

-81.22%

1 Year

-96.17%

2 Years

-99.96%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Aptevo Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

1.16%

EBIT to Interest (avg)

-28.05

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.45

Sales to Capital Employed (avg)

0.14

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.15%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.27

EV to EBIT

0.61

EV to EBITDA

0.62

EV to Capital Employed

4.47

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

727.66%

ROE (Latest)

-160.72%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (1.98%)

Foreign Institutions

Held by 6 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 35.56% vs -45.16% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.90",
          "val2": "-7.60",
          "chgp": "22.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.80",
          "val2": "-9.00",
          "chgp": "35.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -7.88% vs -29.57% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.10",
          "val2": "-24.20",
          "chgp": "-7.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.00",
          "val2": "-24.10",
          "chgp": "-7.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.90

-7.60

22.37%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-5.80

-9.00

35.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 35.56% vs -45.16% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-26.10

-24.20

-7.85%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-26.00

-24.10

-7.88%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -7.88% vs -29.57% in Dec 2024

All Annual Results

Company CV

About Aptevo Therapeutics, Inc.

Aptevo Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).

Company Coordinates

Company Details

2401 4th Ave Ste 1050 , SEATTLE WA : 98121-3460

Tel: 1 206 8380500

http://aptevotherapeutics.com/

Registrar Details